PDS Planning Inc Has $416,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

PDS Planning Inc decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,725 shares of the medical instruments supplier’s stock after selling 129 shares during the quarter. PDS Planning Inc’s holdings in Becton, Dickinson and Company were worth $416,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Counselors Inc. boosted its position in Becton, Dickinson and Company by 12.6% in the first quarter. Financial Counselors Inc. now owns 1,515 shares of the medical instruments supplier’s stock valued at $375,000 after buying an additional 169 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Becton, Dickinson and Company during the first quarter worth approximately $252,000. TFB Advisors LLC lifted its holdings in Becton, Dickinson and Company by 17.5% in the first quarter. TFB Advisors LLC now owns 1,410 shares of the medical instruments supplier’s stock valued at $330,000 after buying an additional 210 shares during the period. 9258 Wealth Management LLC bought a new position in Becton, Dickinson and Company in the first quarter valued at approximately $203,000. Finally, DAVENPORT & Co LLC grew its holdings in Becton, Dickinson and Company by 2,495.2% during the 1st quarter. DAVENPORT & Co LLC now owns 225,680 shares of the medical instruments supplier’s stock worth $55,790,000 after acquiring an additional 216,984 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.4 %

Shares of NYSE:BDX opened at $234.33 on Tuesday. The firm has a fifty day moving average price of $237.52 and a two-hundred day moving average price of $235.10. The company has a market cap of $67.73 billion, a price-to-earnings ratio of 48.22, a PEG ratio of 1.75 and a beta of 0.43. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $259.92.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BDX shares. Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Raymond James lowered their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.